# To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Source: https://onco.cc/trials/nct05468489/  
OnCo record `nct05468489` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Serplulimab, Atezolizumab in small-cell lung cancer, run by Shanghai Henlius Biotech, active and no longer recruiting.

## Summary

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC is a phase 3 interventional study registered as NCT05468489 by Shanghai Henlius Biotech, with 200 participants planned, started 2022-11-18 and due to reach its primary completion in 2026-02-28. Interventions recorded: Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide). Conditions listed: Extensive Stage Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05468489
- Phase: 3
- Setting: A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)
- Sponsor: Shanghai Henlius Biotech
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT05468489: https://clinicaltrials.gov/study/NCT05468489

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Serplulimab](https://onco.cc/drugs/serplulimab/)
- companies: [Shanghai Henlius Biotech](https://onco.cc/companies/henlius/)

---
JSON: https://onco.cc/api/v1/entities/nct05468489.json